Pancreatic Cancer Research

ResearcherNara Medical UniversityActive in the last 2 years

Taichi Terai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2161-9158; OpenAlex author ID A5083789490. Sources: OpenAlex.

Their work

Papers
19 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
52
Papers, trials and grants by year

2021: 2 papers · 2022: 1 paper · 2023: 9 papers · 2024: 6 papers · 2025: 1 paper

Papers 19

  1. An axon guidance-related microRNA panel identifies perivascular plexus local recurrence following curative surgery in patients with pancreatic cancer. Co-author DOI 10.1007/s00535-025-02260-w↗
  2. Total neoadjuvant therapy improves survival of patients with borderline resectable pancreatic cancer with arterial involvement. First author DOI 10.1002/ags3.12726↗
  3. Prognostic significance of creatine kinase in resected pancreatic cancer. Co-author DOI 10.1002/jhbp.12081↗
  4. Feasibility and efficacy of cell-free and concentrate ascites reinfusion therapy (CART) for advanced pancreatic cancer patients with massive malignant ascites. First author DOI 10.1016/j.pan.2024.07.013↗
  5. Clinical impact of carbonic anhydrase 9 expression on neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2024.08.003↗
  6. Clinical significance and therapeutic implication of CD200 in pancreatic cancer. First author DOI 10.1016/j.pan.2024.10.007↗
  7. Critical Role of Preoperative Hyperglycemia in Association with GFAT-1 Expression in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-15985-4↗
  8. Importance of triple tumor markers as biomarkers in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12629↗
  9. Essential updates 2021/2022: Surgical outcomes of oligometastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12655↗
  10. Gastrojejunostomy versus endoscopic duodenal stent placement for gastric outlet obstruction in patients with unresectable pancreatic cancer: a propensity score… Co-author DOI 10.1007/s00464-022-09685-x↗
  11. Significance of multiple tumor markers measurements in conversion surgery for unresectable locally advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2023.06.001↗
  12. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery… Co-author DOI 10.1016/j.pan.2023.07.005↗
  13. Combination of carbohydrate antigen 19-9 level and tumor size after neoadjuvant chemoradiation therapy may predict early recurrence of resectable pancreatic du… Co-author DOI 10.1016/j.pan.2023.10.014↗
  14. Clinical significance and functional role of adhesion G-protein-coupled receptors in human pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-022-02057-1↗
  15. Identification of Nectin Family Interactive Gene Panel and Stratification of Clinical Outcomes in Patients with Pancreatic Cancer. Co-author DOI 10.1097/xcs.0000000000000808↗
  16. Pancreatic ductal adenocarcinoma arising from the pancreatic parenchyma compressed by a huge pancreatic lipoma: a case report. Co-author DOI 10.1186/s40792-023-01720-w↗
  17. Integrative analysis identifies activated anti-tumor immune microenvironment in lung metastasis of pancreatic cancer. Co-author DOI 10.1007/s10147-022-02131-x↗
  18. Clinical relevance of CD70 expression in resected pancreatic cancer: Prognostic value and therapeutic potential. Co-author DOI 10.1016/j.pan.2021.01.013↗
  19. Does direct invasion of peripancreatic lymph nodes impact survival in patients with pancreatic ductal adenocarcinoma? A retrospective dual-center study. Co-author DOI 10.1016/j.pan.2021.03.008↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masayuki Sho · 19 shared papers, 2021–2025 · strength 3.44
  2. Minako Nagai · 18 shared papers, 2021–2025 · strength 3.29
  3. Satoshi Yasuda · 14 shared papers, 2022–2025 · strength 2.75
  4. Yuichiro Kohara · 13 shared papers, 2023–2025 · strength 2.60
  5. Kota Nakamura · 13 shared papers, 2021–2025 · strength 2.47
  6. Satoshi Nishiwada · 8 shared papers, 2021–2025 · strength 1.39
  7. Kenji Nakagawa · 4 shared papers, 2021–2023 · strength 0.56
  8. Takahiro Akahori · 3 shared papers, 2021–2024 · strength 0.45
  9. Tadataka Takagi · 3 shared papers, 2021–2023 · strength 0.42
  10. Tsutomu Fujii · 2 shared papers, 2023 · strength 0.30
  11. Ippei Matsumoto · 2 shared papers, 2023 · strength 0.28
  12. So Yamaki · 2 shared papers, 2021–2023 · strength 0.24
  13. Sohei Satoi · 2 shared papers, 2021–2023 · strength 0.24
  14. Daisuke Hashimoto · 2 shared papers, 2021–2023 · strength 0.24
  15. Tomohisa Yamamoto · 2 shared papers, 2021–2023 · strength 0.24
  16. Toshihiro Tanaka · 1 shared paper, 2025 · strength 0.23
  17. Chiharu Uchiyama · 1 shared paper, 2024 · strength 0.21
  18. Shoichi Kinoshita · 1 shared paper, 2024 · strength 0.19
  19. Yuki Imazu · 1 shared paper, 2023 · strength 0.18
  20. Suguru Yamada · 1 shared paper, 2023 · strength 0.17
  21. Kensuke Yamamura · 1 shared paper, 2023 · strength 0.17
  22. Yasuhiro Kodera · 1 shared paper, 2023 · strength 0.17
  23. Ajay Goel · 1 shared paper, 2023 · strength 0.17
  24. Kohei Morita · 1 shared paper, 2023 · strength 0.16
  25. Seiji Nakahara · 1 shared paper, 2023 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.